舒尼替尼
受体酪氨酸激酶
酪氨酸激酶抑制剂
血管生成
癌症研究
酪氨酸激酶
血小板源性生长因子受体
激酶
药理学
医学
生物
受体
信号转导
癌症
细胞生物学
内科学
生长因子
作者
Connie L. Sun,James G. Christensen,Gerald McMahon
标识
DOI:10.1002/9780470524961.ch1
摘要
This chapter contains sections titled: Sunitinib Receptor Tyrosine Kinase Signaling Affects Multiple and Diverse Cancer Processes Role of Receptor Tyrosine Kinases in Pathologic Tumor Angiogenesis SU 5416: Discovery of First-Generation VEGFR RTK Inhibitors SU 6668: Inhibitor of PDGFR and VEGFR Tyrosine Kinases Design, Discovery, and Development Rationale for SU 11248 SU 11248 in vitro Protein Kinase Target Profile Simultaneous Inhibition of VEGFR, PDGFR, and KIT (SCFR) RTKs Established a Unique Mechanism of Action for SU 11248 SU 11248 PKPD Studies Established the Optimal Dosing Parameters SU 11248 Nonclinical Studies Supported Clinical Strategy and Tumor Indication Selection SU 11248: Translational Studies Provided a Drug Registration Path Summary Acknowledgments References
科研通智能强力驱动
Strongly Powered by AbleSci AI